OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi^® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.